Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer
June 14th 2024
E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.